Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) Stock Competitors & Peer Comparison
See CRXT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CRXT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRXT | $0.05 | -31.16% | 0 | -0.02 | -$2.80 | N/A |
| LLY | $1,231.58 | +3.87% | 1.2T | 39.10 | $31.49 | +0.53% |
| JNJ | $261.81 | +0.99% | 630.6B | 24.39 | $10.73 | +2.02% |
| ABBV | $247.91 | +0.76% | 437.9B | 24.32 | $10.19 | +2.78% |
| MRK | $130.90 | +1.80% | 323.3B | 40.78 | $3.21 | +2.57% |
| NVS | $156.79 | +0.29% | 298B | 18.04 | $8.69 | +3.03% |
| AZN | $161.91 | +0.30% | 251.1B | 17.48 | $9.26 | +1.29% |
| AMGN | $417.20 | +3.05% | 221.8B | 18.37 | $22.37 | +2.37% |
| NVO | $47.73 | +0.99% | 212B | 11.87 | $4.02 | +3.81% |
| GILD | $133.06 | -0.11% | 165.2B | -341.18 | -$0.39 | +2.42% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
CRXT vs LLY Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while LLY trades at $1,231.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas LLY's P/E ratio is 39.10. In terms of profitability, CRXT's ROE is -4.63%, compared to LLY's ROE of +0.93%. Regarding short-term risk, CRXT is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
CRXT vs JNJ Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, JNJ has a market cap of 630.6B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while JNJ trades at $261.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas JNJ's P/E ratio is 24.39. In terms of profitability, CRXT's ROE is -4.63%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, CRXT is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
CRXT vs ABBV Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, ABBV has a market cap of 437.9B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while ABBV trades at $247.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas ABBV's P/E ratio is 24.32. In terms of profitability, CRXT's ROE is -4.63%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, CRXT is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
CRXT vs MRK Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, MRK has a market cap of 323.3B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while MRK trades at $130.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas MRK's P/E ratio is 40.78. In terms of profitability, CRXT's ROE is -4.63%, compared to MRK's ROE of +0.07%. Regarding short-term risk, CRXT is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check MRK's competition here
Novartis AG (NYSE: NVS)
CRXT vs NVS Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, NVS has a market cap of 298B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while NVS trades at $156.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas NVS's P/E ratio is 18.04. In terms of profitability, CRXT's ROE is -4.63%, compared to NVS's ROE of +0.30%. Regarding short-term risk, CRXT is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
CRXT vs AZN Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, AZN has a market cap of 251.1B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while AZN trades at $161.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas AZN's P/E ratio is 17.48. In terms of profitability, CRXT's ROE is -4.63%, compared to AZN's ROE of +0.22%. Regarding short-term risk, CRXT is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
CRXT vs AMGN Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while AMGN trades at $417.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas AMGN's P/E ratio is 18.37. In terms of profitability, CRXT's ROE is -4.63%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, CRXT is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
CRXT vs NVO Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, NVO has a market cap of 212B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while NVO trades at $47.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas NVO's P/E ratio is 11.87. In terms of profitability, CRXT's ROE is -4.63%, compared to NVO's ROE of +0.59%. Regarding short-term risk, CRXT is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
CRXT vs GILD Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GILD has a market cap of 165.2B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while GILD trades at $133.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GILD's P/E ratio is -341.18. In terms of profitability, CRXT's ROE is -4.63%, compared to GILD's ROE of -0.16%. Regarding short-term risk, CRXT is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
CRXT vs PFE Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, PFE has a market cap of 154.2B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while PFE trades at $27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas PFE's P/E ratio is 8.87. In terms of profitability, CRXT's ROE is -4.63%, compared to PFE's ROE of +0.05%. Regarding short-term risk, CRXT is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
CRXT vs BMY Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BMY has a market cap of 132.5B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while BMY trades at $64.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BMY's P/E ratio is 10.94. In terms of profitability, CRXT's ROE is -4.63%, compared to BMY's ROE of +0.47%. Regarding short-term risk, CRXT is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check BMY's competition here
GSK plc (NYSE: GSK)
CRXT vs GSK Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GSK has a market cap of 104.6B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while GSK trades at $52.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GSK's P/E ratio is 11.27. In terms of profitability, CRXT's ROE is -4.63%, compared to GSK's ROE of +0.24%. Regarding short-term risk, CRXT is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check GSK's competition here
Sanofi (NASDAQ: SNY)
CRXT vs SNY Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while SNY trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SNY's P/E ratio is 9.47. In terms of profitability, CRXT's ROE is -4.63%, compared to SNY's ROE of +0.06%. Regarding short-term risk, CRXT is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check SNY's competition here
Zoetis Inc. (NYSE: ZTS)
CRXT vs ZTS Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, ZTS has a market cap of 31.4B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while ZTS trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas ZTS's P/E ratio is 11.37. In terms of profitability, CRXT's ROE is -4.63%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, CRXT is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check ZTS's competition here
Biogen Inc. (NASDAQ: BIIB)
CRXT vs BIIB Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BIIB has a market cap of 30.6B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while BIIB trades at $207.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BIIB's P/E ratio is 13.08. In terms of profitability, CRXT's ROE is -4.63%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, CRXT is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
CRXT vs HZNP Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CRXT's ROE is -4.63%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CRXT is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
CRXT vs GRFS Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while GRFS trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GRFS's P/E ratio is 9.25. In terms of profitability, CRXT's ROE is -4.63%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, CRXT is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
CRXT vs OGN Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while OGN trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas OGN's P/E ratio is 4.07. In terms of profitability, CRXT's ROE is -4.63%, compared to OGN's ROE of +0.23%. Regarding short-term risk, CRXT is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CRXT vs CELG-RI Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, CELG-RI has a market cap of 206.3M. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CRXT's ROE is -4.63%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CRXT is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CRXT vs CTOR Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, CTOR has a market cap of 70.2M. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas CTOR's P/E ratio is -1.61. In terms of profitability, CRXT's ROE is -4.63%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, CRXT is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLXW)
CRXT vs SCLXW Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, CRXT's ROE is -4.63%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, CRXT is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check SCLXW's competition here
Scilex Holding Company (NASDAQ: SCLX)
CRXT vs SCLX Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SCLX has a market cap of 56.8M. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while SCLX trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SCLX's P/E ratio is -0.17. In terms of profitability, CRXT's ROE is -4.63%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, CRXT is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
CRXT vs MIRA Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, MIRA has a market cap of 32.2M. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while MIRA trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas MIRA's P/E ratio is -0.53. In terms of profitability, CRXT's ROE is -4.63%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, CRXT is more volatile compared to MIRA. This indicates higher risk in terms of short-term price fluctuations for CRXT.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
CRXT vs BDSIW Comparison August 2026
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CRXT is priced at $0.05 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, CRXT's ROE is -4.63%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CRXT is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for CRXT.Check BDSIW's competition here